News | February 23, 2024
Moderna posts Q4 2023 revenue at US$ 2.8 billion
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York
India’s First Integrated Ayush Wellness Centre to come up in Guwahati, foundation stone laid
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Subscribe To Our Newsletter & Stay Updated
